Tag: sickle cell

Sickle Cell Disease (SCD) remains a silent scourge—a genetic disorder passed down with the heavy hand of biology but sustained through societal neglect. In Nigeria, the burden is not only colossal—it is tragically preventable. The figures are staggering: each year, of the 400,000 babies born globally with SCD, an estimated 150,000 are Nigerian. This is not just a statistical concern; it is a human crisis unfolding with relentless regularity, leaving shattered families and stunted futures in its wake.

Despite an expanding body of scientific knowledge and the proliferation of public awareness campaigns, Nigeria continues to witness an alarming rise in new cases. This painful paradox lies not in a lack of medical solutions, but in a persistent failure to embrace the simplest of preventive measures: genotype testing and informed marital choices. At the heart of the SCD epidemic is a biological truth long understood yet insufficiently acted upon. The disease manifests when a child inherits two abnormal haemoglobin genes—typically the result of a union between two carriers of the AS genotype.Each pregnancy between such partners carries a 25 per cent chance of producing a child with full-blown sickle cell disease. In a country teeming with information outlets, mobile health innovations, and religious institutions of influence, the question looms: why do these unions persist?

The answer is a blend of ignorance, cultural inertia, romantic idealism, and inadequate policy enforcement. The consequences, however, are uniform—lifelong suffering for children born with SCD, crushing emotional and financial burdens on families, and a strain on an already overburdened healthcare system. Prof Titus Ibekwe, Provost of the College of Health Sciences at the University of Abuja, captured the gravity of the situation in stark terms during a recent public lecture. “Prevention is key in the fight against sickle cell,” he stated. “And this costs nothing.” Indeed, a simple blood test to determine genotype, followed by informed partner selection, could potentially prevent tens of thousands of new cases each year. That this life-saving intervention is not yet universal practice is both a tragedy and an indictment.

In matters of public health, prevention has always been more cost-effective, equitable, and sustainable than treatment. This maxim rings particularly true for sickle cell disease. While advances in therapeutics—from hydroxyurea to bone marrow transplantation and emerging gene therapies—offer hope, they remain inaccessible luxuries for the majority of Nigerians. Hydroxyurea, a medication that reduces painful episodes and improves survival, requires consistent access and monitoring. Bone marrow transplants, though potentially curative, are invasive, costly, and suitable only for a subset of patients. Gene therapies, still nascent and prohibitively expensive, are not a realistic solution for most. Even if these treatments were more widely available, they would not eliminate the sickle cell mutation from reproductive DNA—thus perpetuating the genetic transmission to future generations.

READ ALSO: Why is Nasir El-Rufai so desperate?

As Dr. Maureen Achebe of Harvard Medical School aptly stated, “Treatment is essential, but prevention is transformative.” Achebe, a globally respected haematologist and herself of Nigerian descent, has long called for a multipronged strategy: universal new-born screening, early diagnosis, public education, and culturally attuned advocacy. Her warnings are not merely clinical; they are deeply humanitarian. Without early identification and sustained intervention, children with SCD face death before age five—many undiagnosed, others misdiagnosed, most underserved.

The disparities in outcomes between high-income and low-income countries speak volumes about the injustice embedded in this crisis. According to the U.S. Centres for Disease Control and Prevention, while the average life expectancy for SCD patients in high-income countries exceeds 57 years, between 50 and 80 per cent of affected children in Sub-Saharan Africa die before their fifth birthday. In the United States, the survival rate for SCD babies reaching adulthood is an encouraging 95 per cent. In Nigeria, this optimism is often a luxury.

This is not merely a health crisis—it is a health equity crisis. The lives of children born into poverty, born into ignorance, born into regions where cultural myths outweigh clinical facts, are being sacrificed on the altar of inertia. What is at stake is not only health but the right to life and dignity.

Achebe’s voice joins a growing chorus of advocates, researchers, and clinicians who believe that Nigeria can and must rise to this challenge. Among them is Prof Obiageli Nnodu, Director of the Centre of Excellence for Sickle Cell Disease Research and Training (CESRTA) at the University of Abuja. Since its founding in 2015, CESRTA has made impressive strides—combining rigorous research with outreach and policy advocacy. Its recent elevation to a National Centre of Excellence following the 5th Global Congress on Sickle Cell Disease reflects not only its achievements but also the growing momentum to localise leadership in the fight against SCD. Yet, as Nnodu rightly insists, “Research must lead to action.” That action must be multifaceted—policy reforms, mass education, and institutionalised genotype screening. The time for tokenism is over.

The economic cost of SCD to Sub-Saharan Africa is estimated at over $9.1 billion annually, a figure projected to cross the $10 billion threshold by 2030. Much of this is avoidable. Frequent hospitalisations, loss of workforce productivity, premature deaths, and the emotional toll on caregivers all add up. The cost of inaction is far greater than the cost of prevention. Achebe’s prescription is sobering: what is needed is not merely more funding—but political will, system-wide reforms, and a national ethos that prioritises preventive health.

It is no longer sufficient to relegate genotype testing to occasional awareness campaigns or optional premarital advice. Genotype matching must be codified into national policy. Universal new-born screening must become a statutory obligation. Religious organisations, which still conduct the vast majority of weddings in Nigeria, should be mandated to verify genotype compatibility before officiating unions. Additionally, state governments must follow the example of progressive public health agencies by investing in mobile genotype testing units, especially for underserved rural populations. Digital technologies—mobile apps, SMS campaigns, social media platforms—can amplify the message and connect users with nearby testing centres. Moreover, existing national health frameworks must be revised to incorporate SCD prevention as a priority. From public education curricula to traditional leaders’ councils, the message must be loud, clear, and relentless: love is not enough—genotype compatibility saves lives.

Cultural and religious institutions wield enormous influence in Nigeria. These platforms must not be ignored. Clerics, imams, and traditional rulers must become allies in the campaign against preventable SCD. Community-based advocacy—through storytelling, testimonies, and relatable messaging—can help challenge stigma, correct misinformation, and shift public perception. The silence that shrouds SCD must be broken. Too many parents discover the genotype reality after the tragedy has occurred. Too many children suffer in silence, without proper diagnosis or care. It is time to replace shame with support, silence with education, and neglect with action.

As Nigeria marked World Sickle Cell Day on June 19, the occasion should serve not as an annual formality but as a national reckoning. The path forward is clear: institutionalise genotype screening, legislate premarital testing, invest in prevention, and eliminate the societal myths that have claimed too many innocent lives. This is not just a public health agenda; it is a moral imperative. Nigeria stands at the epicentre of a preventable crisis. The country that gave birth to the most SCD cases annually can also become the first to end the tragedy through coordinated, courageous action. That his tory—written in blood, pain, and resilience—deserves a new chapter. The numbers are too stark to ignore. The stories too painful to forget. The solutions too attainable to delay. Let it begin with matching love not just by heart, but by genotype.

Building positive and non-discriminatory relationships with friends and colleagues who have sickle cell disease (SCD) requires empathy, understanding, and deliberate efforts to foster inclusivity.

Here are practical ways to treat and relate to individuals with SCD as equals while nurturing strong personal and professional bonds:

1. Educate yourself about sickle cell disease

– Learn the basics: Understand SCD’s symptoms, such as pain crises, fatigue, and increased infection risk, as well as triggers like stress or dehydration. This helps you anticipate their needs without making assumptions.

– Ask respectfully: If unsure about their specific experiences, ask open-ended questions like, “How can I support you when you’re not feeling well?” rather than assuming their limitations.

– Stay Informed: Keep up with SCD treatments, like hydroxyurea or pain management strategies, to engage in meaningful conversations and show genuine interest.

2. Show empathy and be a good listener

– Validate Their Feelings: Acknowledge their challenges, whether it’s a pain crisis or frustration with frequent hospital visits.

– Avoid minimizing: Don’t downplay their symptoms or suggest they “push through” fatigue or pain, as this can feel dismissive.

– Be Present: Check in regularly, but respect their space if they need time to rest or recover.

3. Avoid stereotypes and assumptions

– Focus on the person: Treat them as a friend or colleague first, not as “the person with sickle cell.” Engage in conversations about shared interests, work, or hobbies.

– Challenge biases: Avoid assumptions about their capabilities based on their condition. For example, don’t assume they can’t handle certain tasks or social activities without asking.

– Combat Stigma: If others make insensitive comments about SCD or chronic illnesses, gently correct misconceptions to foster a more inclusive environment.

 4. Foster inclusion in social settings (as friends)

– Plan considerate outings: Choose activities that accommodate their needs, like indoor events to avoid extreme weather or venues with easy access to rest areas.

– Be Flexible: Understand if they cancel plans due to a pain crisis or fatigue. Respond with support.

– Celebrate their strengths: Highlight their achievements and qualities, whether it’s their resilience, creativity, or humor, to reinforce their value beyond their condition.

 5. Create a supportive workplace (as colleagues)

– Advocate for accommodations: Support flexible schedules, remote work options, or breaks for hydration and rest, which are critical for managing SCD.

– Collaborate fairly: Include them in team projects and responsibilities based on their skills, not assumptions about their health. If they need adjustments, discuss privately and respectfully.

– Promote awareness: Encourage workplace training on chronic illnesses to reduce stigma and ensure colleagues understand SCD’s impact without singling out the individual.

 6. Offer practical support

– Small gestures matter: Offer to grab water during a meeting, drive them to an appointment, or help with a task during a tough day.

– Respect Their Independence: Don’t assume they always need help; ask first.

– Be reliable: Follow through on promises, whether it’s covering a shift or joining them for a low-key hangout, to build trust.

Read Also: Adekunle Gold launches ‘5 Star Care’ to support sickle cell warriors on World Sickle Cell Day

7. Support their mental and emotional well-being

– Check in emotionally: SCD can be isolating or stressful. Ask to open the door for deeper conversations.

– Encourage Balance: Support their efforts to manage stress, like joining them for a relaxing activity or respecting their need for downtime.

– Be a Cheerleader: Celebrate their milestones, whether personal (e.g., completing a project) or health-related (e.g., managing a crisis well), to boost their confidence.

 8. Advocate for broader change

– Raise awareness: Participate in events like World Sickle Cell Day (June 19) to educate others and amplify the voices of those with SCD.

– Push for equity: Support policies that improve healthcare access or workplace inclusivity, benefiting your friend or colleague and others with chronic conditions.

– Call out discrimination: If you notice unfair treatment, address it tactfully or report it to the appropriate channels to create a safer environment.

By treating friends and colleagues with SCD with the same respect, trust, and camaraderie you’d offer anyone else, while being mindful of their unique needs, you can build strong, equitable relationships. Your actions not only support them but also help dismantle stigma, creating a more inclusive world.

Public health experts have emphasised the urgent need for Nigeria to adopt life-changing gene therapy for the treatment of sickle cell disease.

Official data shows that approximately 4 million Nigerians, about 2% of the population are living with the condition.

Prof. Jennifer Adair, co-founder of the Global Gene Therapy Initiative (GGTI) and faculty member at the University of Massachusetts Chan Medical School, stressed the urgent need to introduce curative treatments such as gene therapy and bone marrow transplants in countries bearing the highest burden of sickle cell disease.

She made this call in Abuja during a press briefing at the 5th Global Sickle Cell Congress, alongside Dr. Alexis Thompson, a physician-scientist at the Children’s Hospital of Philadelphia and a lead investigator in U.S. gene therapy trials, and Jimmy Olaghere, a Nigerian-born recipient of the groundbreaking gene therapy.

Emphasizing the need for Nigeria to formally adopt gene therapy with appropriate administrative structures and legislative support, she noted that embracing the therapy is essential not only for its many benefits but also for advancing scientific progress in the country.

Gene therapy is a medical approach that treats or prevents disease by modifying a person’s genes. It typically involves replacing, repairing, or regulating defective genes—often by introducing a healthy copy to replace a faulty or missing one—thereby addressing the root cause of the condition.

Read Also: Adeboye shares testimonies, urges continued prayers for Nigeria

“Nigeria bears the highest number of sickle cell patients globally. It is vital that those affected, ‘warriors,’ as they are often called, to see that curative options are not science fiction, but real and increasingly within reach,” she said.

She noted that gene therapy is not entirely new to Nigeria, as the country is already part of the GGTI, a coalition of nations committed to building local capacity for research, regulation, and access to gene-based treatments.

According to her, among the first six countries in the network, Uganda has already passed legislation to support bone marrow transplants and gene editing. 

Adair noted that Nigeria has the necessary foundation, scientists, clinicians, regulators, and patient advocates but must align these elements into a cohesive national strategy.

She said Nigeria would not be alone in the process as GGTI also supports knowledge transfer, including training programs between Nigeria, India, and the U.S., and promotes access to technical information in local languages. 

“We are working to support clinicians who want to learn how to manufacture and administer these therapies locally,” she said.

Addressing concerns about affordability in countries with limited healthcare funding, Adair acknowledged the high cost of gene therapy in the U.S., currently ranging between $2 million and $3 million. 

However, she noted that the figures are based on value-based pricing models rather than actual manufacturing costs.

She cited an example from Uganda, where the same therapy could be cost-effective at approximately $40,000, adding, “While $40,000 is still a steep cost, it represents a starting point for investment. 

“With local manufacturing, the cost can fall significantly”. 

Adair referenced the Christian Medical College in Vellore, India, where a similar therapy for cancer is produced for about $35,000, despite importing many materials. 

“With local production and training, prices will drop and capacity will grow,” she added.

On her part, Dr. Thompson described the last decade in hematology as revolutionary, saying, “What was once unthinkable, using a patient’s own genetically modified cells to control or even cure sickle cell disease is now a reality”. 

While acknowledging the risks, including infertility, infection, and rare cases of cancer, she emphasized that many patients have experienced life-changing results. 

“This isn’t for everyone, but for many, the promise of a life without crisis pain is worth the trade-offs,” she explained.

She added that not all sickle cell patients will qualify for gene therapy, noting that eligibility depends on factors such as age, severity of disease, organ health, and willingness to undergo intensive conditioning. 

“But with earlier screening and better interventions, more patients could become eligible over time,” she said.

American-born Jimi Olaghere, who underwent a successful Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene therapy in the United States four years ago, was diagnosed with sickle cell disease before birth.

The Atlanta-based technology entrepreneur shared his personal testimony on the effectiveness of the therapy, saying, “I lived 35 years with pain crises and frequent emergency room visits. Today, I’m virtually pain-free.

“I’ve told my story around the world, but this is the most meaningful stop for me because this is home. 

“The therapy changed my life. From constant hospital visits to climbing Mount Kilimanjaro, the difference is unimaginable.”

Still, he cautioned that the process is not easy, saying, “There’s chemotherapy, hair loss, isolation, it took me nearly a year to recover. But if you’ve lived with sickle cell, you’ve already survived worse”.

Highlighting the scale of Nigeria’s burden, Prof. Obiageli Nnodu, Special Adviser on Sickle Cell Disease to the Coordinating Minister of Health and Chair of the Congress’ Local Organising Committee, noted that data from the 2018 National Demographic and Health Survey showed that around 2% of Nigerians live with the disease, an estimated 4 million people.

She said the staggering figure highlights the need to integrate advanced therapies like gene therapy into Nigeria’s healthcare system. 

“Nigeria continues to bear one of the highest rates of sickle cell disease globally. We cannot ignore curative innovations that have the potential to transform lives,” she said.